联合疗法-话题@MedSci

#联合疗法#

64篇内容 | 1123人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1647013, encodeId=af74164e0132e, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Nature子刊：陈列平教授思考PD-1联合疗法临床试验, objectType=article, longId=729999, objectId=cfe5e2999992, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfe5e2999992, replyNumber=0, likeNumber=48, createdTime=2022-09-09, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfe5e2999992, moduleTitle=Nature子刊：陈列平教授思考PD-1联合疗法临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfe5e2999992)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647010, encodeId=30b8164e010f8, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Carbohydr Polym：化疗-光动力联合疗法治疗银屑病：壳聚糖/透明质酸纳米凝胶共传递甲氨蝶呤和5-氨基乙酰丙酸, objectType=article, longId=293130, objectId=6f36293130d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f36293130d3, replyNumber=0, likeNumber=55, createdTime=2022-08-22, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f36293130d3, moduleTitle=Carbohydr Polym：化疗-光动力联合疗法治疗银屑病：壳聚糖/透明质酸纳米凝胶共传递甲氨蝶呤和5-氨基乙酰丙酸, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f36293130d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647012, encodeId=84ba164e012c9, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Nat Med：胰腺癌免疫联合疗法，一年生存率增加近65%！, objectType=article, longId=729392, objectId=cb2ee293927d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2ee293927d, replyNumber=0, likeNumber=57, createdTime=2023-02-04, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2ee293927d, moduleTitle=Nat Med：胰腺癌免疫联合疗法，一年生存率增加近65%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb2ee293927d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647008, encodeId=7c14164e0088f, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=新冠特效药来了！我国新冠中和抗体联合疗法获批, objectType=article, longId=221785, objectId=898a221e855c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=898a221e855c, replyNumber=0, likeNumber=32, createdTime=2022-01-04, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=898a221e855c, moduleTitle=新冠特效药来了！我国新冠中和抗体联合疗法获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=898a221e855c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647006, encodeId=e157164e00617, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=AJRCCM：肺动脉高压联合疗法、分阶段及目标导向疗法, objectType=article, longId=218631, objectId=0cea218631ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cea218631ef, replyNumber=0, likeNumber=37, createdTime=2022-07-25, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cea218631ef, moduleTitle=AJRCCM：肺动脉高压联合疗法、分阶段及目标导向疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cea218631ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647011, encodeId=8275164e0110e, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=默克与思路迪医药达成临床研究合作，共同探索创新“靶向+肿瘤免疫”联合疗法治疗转移性结直肠癌, objectType=article, longId=300740, objectId=1daa300e408c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1daa300e408c, replyNumber=0, likeNumber=33, createdTime=2022-10-16, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1daa300e408c, moduleTitle=默克与思路迪医药达成临床研究合作，共同探索创新“靶向+肿瘤免疫”联合疗法治疗转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1daa300e408c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647005, encodeId=b10d164e005ab, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=腾盛博药单克隆抗体联合疗法使住院和死亡复合终点降低78%, objectType=article, longId=216340, objectId=d3282163405f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3282163405f, replyNumber=0, likeNumber=43, createdTime=2022-04-07, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3282163405f, moduleTitle=腾盛博药单克隆抗体联合疗法使住院和死亡复合终点降低78%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3282163405f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647007, encodeId=5b81164e00755, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=JAK抑制剂联合疗法FMX114治疗轻中度特应性皮炎，临床试验中招募了第一位患者, objectType=article, longId=218973, objectId=dbd52189e3d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbd52189e3d5, replyNumber=0, likeNumber=29, createdTime=2022-05-18, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbd52189e3d5, moduleTitle=JAK抑制剂联合疗法FMX114治疗轻中度特应性皮炎，临床试验中招募了第一位患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbd52189e3d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647009, encodeId=8df0164e00943, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=NEJM：Relugolix联合疗法治疗子宫肌瘤, objectType=article, longId=293031, objectId=0376293031b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0376293031b8, replyNumber=0, likeNumber=32, createdTime=2022-01-03, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0376293031b8, moduleTitle=NEJM：Relugolix联合疗法治疗子宫肌瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0376293031b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647000, encodeId=9107164e00034, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Nature Communications：瑞德西韦联合疗法可治疗晚期马尔堡病毒病, objectType=article, longId=209080, objectId=b3c4209080d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3c4209080d8, replyNumber=0, likeNumber=30, createdTime=2021-08-04, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3c4209080d8, moduleTitle=Nature Communications：瑞德西韦联合疗法可治疗晚期马尔堡病毒病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3c4209080d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646999, encodeId=17ae164699971, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验, objectType=article, longId=207256, objectId=1d0f20e25662, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d0f20e25662, replyNumber=0, likeNumber=19, createdTime=2021-12-11, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d0f20e25662, moduleTitle=NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d0f20e25662)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647001, encodeId=1856164e001cd, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=默沙东联合Surface开展联合疗法研究，或将改善K药耐药性, objectType=article, longId=209545, objectId=c8ee20954549, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8ee20954549, replyNumber=0, likeNumber=43, createdTime=2021-09-17, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8ee20954549, moduleTitle=默沙东联合Surface开展联合疗法研究，或将改善K药耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8ee20954549)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647002, encodeId=510a164e00288, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Eur J Cancer：一线免疫检查点抑制剂联合疗法可明显改善转移性尿路上皮癌临床预后, objectType=article, longId=210997, objectId=424321099e06, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=424321099e06, replyNumber=0, likeNumber=33, createdTime=2021-12-26, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=424321099e06, moduleTitle=Eur J Cancer：一线免疫检查点抑制剂联合疗法可明显改善转移性尿路上皮癌临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=424321099e06)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647004, encodeId=77d6164e00417, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=NEJM：达雷木单抗联合疗法有助于改善新诊断AL淀粉样患者预后, objectType=article, longId=213719, objectId=ff64213e19af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff64213e19af, replyNumber=0, likeNumber=37, createdTime=2022-03-07, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff64213e19af, moduleTitle=NEJM：达雷木单抗联合疗法有助于改善新诊断AL淀粉样患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff64213e19af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1647003, encodeId=61b1164e00344, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=Science Tranlational Medicine：为肿瘤免疫疗法“保驾护航”，中美科学家发布全新癌症阻断联合疗法！, objectType=article, longId=213643, objectId=82402136432c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82402136432c, replyNumber=0, likeNumber=49, createdTime=2021-10-14, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82402136432c, moduleTitle=Science Tranlational Medicine：为肿瘤免疫疗法“保驾护航”，中美科学家发布全新癌症阻断联合疗法！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82402136432c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646995, encodeId=bf571646995bd, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=IKCS 2020：基于LENVIMA（lenvatinib）的联合疗法治疗肾细胞癌, objectType=article, longId=203136, objectId=a3c920313621, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3c920313621, replyNumber=0, likeNumber=40, createdTime=2021-09-08, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3c920313621, moduleTitle=IKCS 2020：基于LENVIMA（lenvatinib）的联合疗法治疗肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3c920313621)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646998, encodeId=947f16469986c, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=NEJM：Relugolix联合疗法治疗子宫肌瘤, objectType=article, longId=207255, objectId=f8f020e25546, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8f020e25546, replyNumber=0, likeNumber=41, createdTime=2021-03-15, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8f020e25546, moduleTitle=NEJM：Relugolix联合疗法治疗子宫肌瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8f020e25546)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646993, encodeId=d1671646993a0, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=JCC: 生物制剂和免疫调节剂联合疗法优于单一疗法，可减少与炎症性肠病相关并发症的风险, objectType=article, longId=201872, objectId=a9822018e210, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9822018e210, replyNumber=0, likeNumber=44, createdTime=2020-10-17, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9822018e210, moduleTitle=JCC: 生物制剂和免疫调节剂联合疗法优于单一疗法，可减少与炎症性肠病相关并发症的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9822018e210)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646997, encodeId=4b00164699e99, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=J Clin Oncol：以达雷木单抗联合疗法治疗多发性骨髓瘤的持续性MRD阴性情况（POLLUX和CASTOR）, objectType=article, longId=206596, objectId=62c62065968a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62c62065968a, replyNumber=0, likeNumber=28, createdTime=2021-07-28, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62c62065968a, moduleTitle=J Clin Oncol：以达雷木单抗联合疗法治疗多发性骨髓瘤的持续性MRD阴性情况（POLLUX和CASTOR）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62c62065968a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1646987, encodeId=8adb164698eac, content=<a href='/topic/show?id=0eb280e174e' target=_blank style='color:#2F92EE;'>#联合疗法#</a>, objectTitle=西奈山索伦托合作开发针对新冠病毒COVID-19的三抗体联合疗法COVI-SHIELD, objectType=article, longId=193859, objectId=b66d1938590a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b66d1938590a, replyNumber=0, likeNumber=34, createdTime=2020-05-10, rootId=0, userName=wincls, userId=2fce23370592, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b66d1938590a, moduleTitle=西奈山索伦托合作开发针对新冠病毒COVID-19的三抗体联合疗法COVI-SHIELD, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b66d1938590a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合疗法

2020-05-29

wincls (审核中...)

前往app查看评论内容

#联合疗法#

Nature子刊：陈列平教授思考PD-1联合疗法临床试验

2022-09-09

wincls (审核中...)

前往app查看评论内容

#联合疗法#

Carbohydr Polym：化疗-光动力联合疗法治疗银屑病：壳聚糖/透明质酸纳米凝胶共传递甲氨蝶呤和5-氨基乙酰丙酸

2022-08-22

wincls (审核中...)

前往app查看评论内容

#联合疗法#

Nat Med：胰腺癌免疫联合疗法，一年生存率增加近65%！

2023-02-04

wincls (审核中...)

前往app查看评论内容

#联合疗法#

新冠特效药来了！我国新冠中和抗体联合疗法获批

2022-01-04

wincls (审核中...)

前往app查看评论内容

#联合疗法#

AJRCCM：肺动脉高压联合疗法、分阶段及目标导向疗法

2022-07-25

wincls (审核中...)

前往app查看评论内容

#联合疗法#

默克与思路迪医药达成临床研究合作，共同探索创新“靶向+肿瘤免疫”联合疗法治疗转移性结直肠癌

2022-10-16

wincls (审核中...)

前往app查看评论内容

#联合疗法#

腾盛博药单克隆抗体联合疗法使住院和死亡复合终点降低78%

2022-04-07

wincls (审核中...)

前往app查看评论内容

#联合疗法#

JAK抑制剂联合疗法FMX114治疗轻中度特应性皮炎，临床试验中招募了第一位患者

2022-05-18

wincls (审核中...)

前往app查看评论内容

#联合疗法#

NEJM：Relugolix联合疗法治疗子宫肌瘤

2022-01-03

wincls (审核中...)

前往app查看评论内容

#联合疗法#

Nature Communications：瑞德西韦联合疗法可治疗晚期马尔堡病毒病

2021-08-04

wincls (审核中...)

前往app查看评论内容

#联合疗法#

NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验

2021-12-11

wincls (审核中...)

前往app查看评论内容

#联合疗法#

默沙东联合Surface开展联合疗法研究，或将改善K药耐药性

2021-09-17

wincls (审核中...)

前往app查看评论内容

#联合疗法#

Eur J Cancer：一线免疫检查点抑制剂联合疗法可明显改善转移性尿路上皮癌临床预后

2021-12-26

wincls (审核中...)

前往app查看评论内容

#联合疗法#

NEJM：达雷木单抗联合疗法有助于改善新诊断AL淀粉样患者预后

2022-03-07

wincls (审核中...)

前往app查看评论内容

#联合疗法#

Science Tranlational Medicine：为肿瘤免疫疗法“保驾护航”，中美科学家发布全新癌症阻断联合疗法！

2021-10-14

wincls (审核中...)

前往app查看评论内容

#联合疗法#

IKCS 2020：基于LENVIMA（lenvatinib）的联合疗法治疗肾细胞癌

2021-09-08

wincls (审核中...)

前往app查看评论内容

#联合疗法#

NEJM：Relugolix联合疗法治疗子宫肌瘤

2021-03-15

wincls (审核中...)

前往app查看评论内容

#联合疗法#

JCC: 生物制剂和免疫调节剂联合疗法优于单一疗法，可减少与炎症性肠病相关并发症的风险

2020-10-17

wincls (审核中...)

前往app查看评论内容

#联合疗法#

J Clin Oncol：以达雷木单抗联合疗法治疗多发性骨髓瘤的持续性MRD阴性情况（POLLUX和CASTOR）

2021-07-28

wincls (审核中...)

前往app查看评论内容

#联合疗法#

西奈山索伦托合作开发针对新冠病毒COVID-19的三抗体联合疗法COVI-SHIELD

2020-05-10

科室
- - 订阅+
  - 更多科室
工具
服务